WaelAHarbMD

Oncology • Newport Beach, CA

Founder of Horizon Oncology Center

Join to view full profile

Dr. Harb is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Harb's full profile

Already have an account?

Office
1441 Avocado Ave
Ste 301
Newport Beach, CA 92660
Phone+1 949-272-2095

Fax+1 949-272-2096

Education & Training

Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 1996 - 1998
Indiana University School of MedicineResidency, Internal Medicine, 1993 - 1996
Damascus University Faculty of MedicineClass of 1992

Certifications & Licensure

CA State Medical License 2021 - 2025
MI State Medical License 2018 - 2023
IN State Medical License 1996 - 2021
American Board of Internal Medicine Medical Oncology

Clinical Trials

Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer Start of enrollment: 2008 Jan 01
Completed
Phase 2
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
COMPLETED
PHASE1, PHASE2
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
COMPLETED
PHASE2
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma Start of enrollment: 2011 Feb 09
Completed
Phase 2
Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors Start of enrollment: 2011 Oct 01
Completed
Phase 1
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment Start of enrollment: 2012 Jan 01
Completed
Phase 1
Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 2012 Nov 01
Completed
Phase 2
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer Start of enrollment: 2013 Sep 06
Completed
Phase 1
ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma Start of enrollment: 2014 Mar 01
TERMINATED
PHASE1, PHASE2
Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors Start of enrollment: 2013 Oct 01
Completed
Phase 1
A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer Start of enrollment: 2014 Mar 05
Completed
Phase 1
Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer. Start of enrollment: 2014 Jun 27
Completed
Phase 1
A Phase 2 Study of CPI-0610 with and Without Ruxolitinib in Patients with Myelofibrosis Start of enrollment: 2014 Jul 16
COMPLETED
PHASE1, PHASE2
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Start of enrollment: 2014 Sep 09
Terminated
Phase 2
A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer Start of enrollment: 2015 Apr 15
Completed
Phase 1, Phase 2
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC Start of enrollment: 2017 Jun 29
Terminated
Phase 2
Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid Tumors Start of enrollment: 2017 Nov 28
Active, not recruiting
Phase 1
Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma Start of enrollment: 2019 Apr 16
COMPLETED
PHASE1
Join now to see all

Publications & Presentations

PubMed

4 citations
Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies.
Eytan M Stein, Amir T Fathi, Wael A Harb, Gozde Colak, Andrea Fusco
Leukemia & Lymphoma. 2024-04-01
13 citations
First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors.
Devalingam Mahalingam, Wael Harb, Amita Patnaik, Andrea Bullock, Randolph S Watnick
Communications Medicine. 2024-01-13
16 citations
Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I ...
Marwan Fakih, Wael Harb, Daruka Mahadevan, Hani Babiker, Jordan Berlin
Journal for Immunotherapy of Cancer. 2023-04-01

Press Mentions

Mediterranean Diet Could Help Lower Cancer Risk in ObesityMarch 2nd, 2025
2 Out of 25 Lifestyle and Environmental Factors Affect Aging the Most, Study FindsFebruary 24th, 2025
How Adjuvant Treatments for Breast Cancer WorkFebruary 5th, 2025
Join now to see all